Edinburgh Study Links DNA Methylation to Ageing Diseases

Researchers led by the University of Edinburgh have identified a rare genetic condition that provides the first direct evidence that the body’s “biological clock” actively drives age-related disease, rather than simply measuring the passage of time. Published in Nature Genetics on 30 June 2026, the study characterizes Heyn-Sproul-Jackson syndrome (HESJAS), a newly described progeria-like disorder that opens a potential route toward future rejuvenation therapies as global life expectancies rise.

DNA methylation marks accumulate on the genome over time and are used to measure biological age. Whether the methylation itself contributes to ageing or merely tracks it passively has been unresolved. HESJAS patients accumulate marks at the same DNA locations as normal ageing but at a substantially faster rate, and develop age-typical conditions much earlier, including reduced blood cell production, infection susceptibility, osteoporosis and hair loss. A mouse model also showed metabolic changes associated with diabetes and elevated cholesterol, alongside adult stem cell dysfunction that may explain the decline in tissue renewal linked to ageing disease.

The study was led by Professor Andrew Jackson at the Institute of Genetics and Cancer, and brought together 76 researchers across seven countries, including the University of Cambridge, the Institute of Cancer Research in London and partners across Spain, France, Norway, Mexico, New Zealand and the United States. Professor Joris Veltman, Director of the Institute, described the findings as identifying promising directions for future rejuvenation therapies. Further work is planned to pinpoint how methylation impairs tissue renewal and to explore ways to reverse it.

For biotech, the finding matters because it shifts DNA methylation from being an age biomarker toward a potential drug target. Emerging longevity-focused biotechs working on epigenetic reprogramming gain new mechanistic support for their approaches, and the finding sharpens the case for pharma partnering. The next commercial signal will be whether major pharma partners begin building methylation-targeted programs into their broader ageing-disease pipelines

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!